Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Multicentre, Ambispective, Observational, Real Life Study to Assess the Quality of Life Effectiveness of Extended Release (ER) Oral Cysteamine Therapy (Procysbi) in Belgian Patients Suffering From Nephropathic Cystinosis

Trial Profile

Multicentre, Ambispective, Observational, Real Life Study to Assess the Quality of Life Effectiveness of Extended Release (ER) Oral Cysteamine Therapy (Procysbi) in Belgian Patients Suffering From Nephropathic Cystinosis

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 30 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Mercaptamine bitartrate (Primary)
  • Indications Nephropathic cystinosis
  • Focus Therapeutic Use
  • Acronyms PROREAL
  • Sponsors Chiesi

Most Recent Events

  • 07 Aug 2020 Planned number of patients changed from 34 to 31.
  • 07 Aug 2020 Planned End Date changed from 1 Mar 2026 to 1 Jul 2026.
  • 07 Aug 2020 Planned primary completion date changed from 1 May 2022 to 1 Jul 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top